- Home
- ACB vs MGNX Comparison
ACB vs MGNX Comparison
Compare ACB & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- MGNX
- Stock Information
- Founded
- ACB 2013
- MGNX 2000
- Country
- ACB Canada
- MGNX United States
- Employees
- ACB N/A
- MGNX N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- MGNX Health Care
- Exchange
- ACB Nasdaq
- MGNX Nasdaq
- Market Cap
- ACB 315.4M
- MGNX 259.3M
- IPO Year
- ACB N/A
- MGNX 2013
- Fundamental
- Price
- ACB $5.50
- MGNX $4.02
- Analyst Decision
- ACB Hold
- MGNX Buy
- Analyst Count
- ACB 1
- MGNX 12
- Target Price
- ACB N/A
- MGNX $8.89
- AVG Volume (30 Days)
- ACB 647.8K
- MGNX 555.4K
- Earning Date
- ACB 11-07-2024
- MGNX 11-04-2024
- Dividend Yield
- ACB N/A
- MGNX N/A
- EPS Growth
- ACB N/A
- MGNX N/A
- EPS
- ACB N/A
- MGNX N/A
- Revenue
- ACB $203,838,819.00
- MGNX $41,018,000.00
- Revenue This Year
- ACB $14.04
- MGNX $110.57
- Revenue Next Year
- ACB $8.94
- MGNX N/A
- P/E Ratio
- ACB N/A
- MGNX N/A
- Revenue Growth
- ACB 12.30
- MGNX N/A
- 52 Week Low
- ACB $2.84
- MGNX $2.95
- 52 Week High
- ACB $9.35
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- ACB 46.30
- MGNX 60.74
- Support Level
- ACB $5.14
- MGNX $3.79
- Resistance Level
- ACB $5.64
- MGNX $4.37
- Average True Range (ATR)
- ACB 0.22
- MGNX 0.24
- MACD
- ACB 0.02
- MGNX 0.08
- Stochastic Oscillator
- ACB 33.03
- MGNX 71.12
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).